(Total Views: 451)
Posted On: 09/03/2020 5:01:08 PM
Post# of 36567
And did i miss when we went from having 400M shares outstanding in NGIO, to now have 400,300,000, an increase of 300K shares?
Quote:
NuGenerex Immuno-Oncology, Inc. (“NGIO”), a Delaware corporation and subsidiary of Generex, has 750,000,000 authorized shares of common stock, 400,300,000 of which are outstanding,
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
